CLRB Phase 2 readout: a positive outcome, +12.4%

On June 22, 2026, Iopofosine I 131 single dose — Cellectar Biosciences, Inc. (Waldenstrom Macroglobulinemia) reached its Phase 2 readout. The result was a positive outcome, and the stock moved +12.4% in the window around the event. It had already run +5.5% in the 30 days into the catalyst — the kind of pre-event run-up that often precedes binary readouts.